A new low-flow ascites pump significantly reduced paracentesis frequency in patients with a contraindication to transjugular intrahepatic portosystemic shunt, or TIPS, according to a recently ...

Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites PARIS & TARRYTOWN, N.Y.-- ...

To the Editor: In the article, "Hemodynamics in the Cirrhotic Patient during Paracentesis." which appeared in the March 2 issue of the Journal, Knauer and Lowe report on circulatory changes occurring ...

Large-volume paracentesis is a treatment used to remove excess fluid in the abdominal cavity resulting from such conditions as cirrhosis of the liver or cardiac failure. It is normally performed as an ...

HealthDay News— Aflibercept, a potent inhibitor of vascular endothelial growth factor (VEGF), shows clinical activity and increases the time to repeat paracentesis for patients with advanced ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of ...

Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit. This is an ASCO Meeting Abstract from the 2011 ASCO ...

HERNIA is known to be more frequent among patients with cirrhosis of the liver, especially with ascites, than among those without liver disease. Chapman et al. 1 reported a rate of 10 per cent in 58 ...

Dyspnea is a frequent complaint in patients with cirrhosis. [3] Dyspnea also occurs in patients without liver disease who suffer from bronchitis, asthma, or chronic lung disease. Some disorders, such ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...